// STATE LEGISLATION TRACKER

Pennsylvania HB 340: An Act amending Title 35 (Health and Safety) of the Pennsylvania Consolidated Statutes, providing for opioid stewardship

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Failed

State: Pennsylvania
Bill: HB 340
Filed: 2021-01-29
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

Pennsylvania HB 340 appears to be an opioid-focused bill creating an opioid reparation/accountability fund and advisory council. Based on the title, action history, and available summary, it does not directly regulate compounded peptides, off-label peptide prescribing, telehealth peptide care, naturopathic or NP scope, or FDA 503A/503B compounding.

Key Points

No clear direct effect on peptide prescriptions or compounded peptide access
No apparent change to telehealth rules for peptide care
No apparent change to NP or naturopathic prescribing scope
No apparent change to 503A/503B compounding rules
Main focus is opioid-related funding and agency duties

What to Watch For

Note Because this is opioid-focused, peptide users mainly need to know it is not a peptide access bill.

Note If later versions add prescribing or pharmacy reporting language, relevance could change.

Note Any opioid-only monitoring changes would not automatically apply to non-controlled peptides.

Where the Bill Stands

HB 340 was referred to the Pennsylvania House Human Services Committee on January 29, 2021, and did not pass before the 2021-2022 session ended.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws